RI7 Stock Overview
Provides molecular beam epitaxy (MBE) products and services for the semiconductor industry. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 6/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Riber S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.50 |
| 52 Week High | €2.84 |
| 52 Week Low | €1.49 |
| Beta | 0.96 |
| 11 Month Change | -3.47% |
| 3 Month Change | 0.40% |
| 1 Year Change | 53.37% |
| 33 Year Change | 61.29% |
| 5 Year Change | 24.07% |
| Change since IPO | -86.49% |
Recent News & Updates
Recent updates
Shareholder Returns
| RI7 | DE Semiconductor | DE Market | |
|---|---|---|---|
| 7D | -1.2% | -1.5% | -0.02% |
| 1Y | 53.4% | -17.3% | 8.2% |
Return vs Industry: RI7 exceeded the German Semiconductor industry which returned -17.3% over the past year.
Return vs Market: RI7 exceeded the German Market which returned 8.2% over the past year.
Price Volatility
| RI7 volatility | |
|---|---|
| RI7 Average Weekly Movement | 4.1% |
| Semiconductor Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: RI7 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: RI7's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1964 | 118 | Annie Geoffroy | www.riber.com |
Riber S.A. provides molecular beam epitaxy (MBE) products and services for the semiconductor industry. It offers MBE systems comprising of research and pilot production system, and solutions for compound semiconductor passivation. In addition, the company provides MBE sources consisting of effusion cells, gas sources, resistive cell, and valved cracker sources, as well as MBE heaters and manipulators.
Riber S.A. Fundamentals Summary
| RI7 fundamental statistics | |
|---|---|
| Market cap | €53.64m |
| Earnings (TTM) | €4.81m |
| Revenue (TTM) | €40.83m |
11.2x
P/E Ratio1.3x
P/S RatioIs RI7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RI7 income statement (TTM) | |
|---|---|
| Revenue | €40.83m |
| Cost of Revenue | €26.73m |
| Gross Profit | €14.09m |
| Other Expenses | €9.29m |
| Earnings | €4.81m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.23 |
| Gross Margin | 34.52% |
| Net Profit Margin | 11.77% |
| Debt/Equity Ratio | 22.0% |
How did RI7 perform over the long term?
See historical performance and comparison